Market Place
Sourcing Support
Chiesi Reports Phase 3 Results of ELFABRIO® in Fabry Disease
28 Oct 2024 //
PR NEWSWIRE
Chiesi`s New Biotech Center of Excellence Opens in Parma, Italy
14 Oct 2024 //
PR NEWSWIRE
Chiesi USA Releases 2023 Sustainability Report
09 Oct 2024 //
GLOBENEWSWIRE
Oak Hill Bio, Chiesi Enroll First BPD Prevention Phase 2b
17 May 2024 //
PR NEWSWIRE
Chiesi Group signs MoU with Karolinska Institutet to tackle urgent challenges
16 May 2024 //
PHARMABIZ
Chiesi Group Forges Allianc, Karolinska to Tackle Urgent Health Challenges
15 May 2024 //
PHARMIWEB
Sanofi, Pfizer, AZ lead biopharma industry investment in France
13 May 2024 //
FIERCE PHARMA
Gossamer Bio and Chiesi partner for pulmonary hypertension treatment
06 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Gossamer Bio and Chiesi Group collaborate on Seralutinib for pulmonary diseases.
06 May 2024 //
BUSINESSWIRE
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
06 May 2024 //
REUTERS
Chiesi champions new inhaler propellant to reduce carbon footprint
22 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
Chiesi Global Presents Long-Term Data on Treatment with Velmanase Alfa
08 Feb 2024 //
PR NEWSWIRE
Chiesi Group and Oak Hill Bio announce License and Development Agreement
09 Jan 2024 //
BUSINESSWIRE
Chiesi Group and Oak Hill Bio announce License and Development Agreement
08 Jan 2024 //
PR NEWSWIRE
Chiesi works with BBC to spread message about greener inhalers
05 Dec 2023 //
FIERCE PHARMA
Chiesi Group signed a License Agreement with Haisco Pharmaceutical
20 Nov 2023 //
PR NEWSWIRE
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
05 Sep 2023 //
PM LIVE
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
31 Jul 2023 //
GLOBENEWSWIRE
Kindeva Drug Delivery, Chiesi Group, and H&T Presspart Team Up
19 Jul 2023 //
CONTRACT PHARMA
Chiesi, Protalix`s Fabry disease approved as Elfabrio joins Fabrazyme
10 May 2023 //
ENDPTS
Europe signs off on Protalix, Chiesi`s Fabry disease treatment
06 May 2023 //
FIERCE PHARMA
Chiesi Continues International Growth Surge
10 Apr 2023 //
CONTRACT PHARMA
Chiesi, Affibody sign $637M respiratory disease collab
08 Mar 2023 //
FIERCE BIOTECH
Pilloxa Signs a Agreement with Chiesi in Germany with a Value of SEK 1 million
07 Mar 2023 //
ACCESSWIRE
Protalix & Chiesi gain positive opinion for pegunigalsidase alfa
06 Mar 2023 //
PHARMATIMES
Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa
25 Feb 2023 //
BIOSPACE
Chiesi Global Rare Diseases Presents Results from PIII BALANCE & BRIGHT Studies
24 Feb 2023 //
PR NEWSWIRE
Chiesi gets FDA high five for enzyme replacement therapy Lamzede
18 Feb 2023 //
FIERCE PHARMA
Chiesi`s Biologic Lamzede (Velmanase alfa) Receives Approval in the U.S.
16 Feb 2023 //
FDA
After Amryt buy, Chiesi names Baxter vet Accogli its new CEO
30 Jan 2023 //
FIERCE PHARMA
Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout
09 Jan 2023 //
FIERCE PHARMA
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
08 Jan 2023 //
GLOBENEWSWIRE
Chiesi Sues Aurobindo to Block Copies of Kengreal Anti-Clot Drug
05 Jan 2023 //
BLOOMBERG LAW
Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence
25 Nov 2022 //
PHARMAPHORUM
After CRL, drug developer duo resubmits its experimental drug to the FDA
15 Nov 2022 //
ENDPTS
Protalix & Chiesi Announce Resubmission of BLA to FDA for Pegunigalsidase Alfa
14 Nov 2022 //
PRNEWSWIRE
Aptar and Chiesi Sign Contract to bring Best Disease Management Platform
18 Oct 2022 //
BUSINESSWIRE
FDA starts review of first drug for alpha-mannosidosis, from Chiesi
13 Sep 2022 //
PHARMAPHORUM
Chiesi USA Reports Progress in ASHP Foundation’s Pharmacy Leadership Scholars
06 Sep 2022 //
GLOBENEWSWIRE
NHS Scotland recommends Chiesi’s Trimbow for asthma
18 Aug 2022 //
PHARMAFILE
Chiesi reinforces commitment to reducing emissions
27 Jul 2022 //
PHARMATIMES
Chiesi Group joins White House pledge to decarbonize healthcare sector
25 Jul 2022 //
GLOBENEWSWIRE
Chiesi tracks actions taken for a healthier, more sustainable future
14 Jul 2022 //
GLOBENEWSWIRE
Chiesi enlists support for nose-to-brain biologic delivery push
11 Jul 2022 //
FIERCEPHARMA
Chiesi supports painted hospitals project
03 Jun 2022 //
FIERCEPHARMA
Chiesi Global Rare Diseases Announces Support for Jeffrey Modell Foundation
01 Jun 2022 //
PRNEWSWIRE
Chiesi acquires pioneering therapeutic MAb portfolio against EMAP II
02 May 2022 //
PRNEWSWIRE
CHIESI GROUP CONTINUES GROWTH
01 Apr 2022 //
PRNEWSWIRE
Chiesi and Protalix announce Phase III data from BRIGHT study in Fabry disease
19 Mar 2022 //
THEPHARMALETTER
Chiesi USA donates more than $815,000 to local communities and nonprofits
16 Mar 2022 //
GLOBENEWSWIRE
Protalix Bio, Chiesi Global Rare Diseases Submit MAA to EMA for PRX-102
24 Feb 2022 //
PRNEWSWIRE
Chiesi Global Rare Diseases Announces Updated U.S. Prescribing FERRIPROX
05 Dec 2021 //
PRNEWSWIRE
Protalix Biotherapeutics & Chiesi Global Rare Diseases Provide Regulatory Update
11 Oct 2021 //
PRNEWSWIRE
Protalix sees a path for Fabry resubmission down the line
11 Oct 2021 //
FIERCEBIOTECH
Chiesi accelerates its transition in favor of sustainable development
06 Jul 2021 //
BUSINESSWIRE
Chiesi Accelerates Path Toward Full Sustainability Despite Covid-19 Pandemic
23 Jun 2021 //
BUSINESSWIRE
Icario and ConnectureDRX Partner to Deliver a Seamless Enrollment Experience
23 Jun 2021 //
GLOBENEWSWIRE
Chiesi`s Raxone recommended for use within NHS Wales
26 Apr 2021 //
PHARMATIMES
Chiesi Group receives European Marketing Authorization for Trimbow®
21 Apr 2021 //
GLOBENEWSWIRE
